India has revoked a patent granted to GlaxoSmithKline Plc for breast cancer drug Tykerb, a decision that follows a landmark India court ruling disallowing patents for incremental innovations that......
After hiving off its non-oncology drugs business last year, the Dabur group recently divested its entire stake in Dabur Pharma to Fresenius Kabi, a 100 per cent subsidiary of the Germany-based......
In a move to focus on its core FMCG strength, the Burman family, promoters of Dabur India, last week announced their exit from the pharma business. The Burmans sold Dabur Pharma - the oncology......